Pfizer Reported Positive Phase 3 Results for Litfulo
The drug showed promise as a systemic vitiligo treatment in recent clinical trials.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Do you prefer oral medication over topical creams for treating long-term skin conditions?
Pfizer has announced positive phase 3 results for its drug Litfulo in treating patients with nonsegmental vitiligo. The company intends to seek regulatory approval for the oral Janus kinase inhibitor as a vitiligo therapy from the FDA and European Medicines Agency.
Why it matters
Topical treatments for vitiligo are often restricted by the limited body surface area they can effectively cover. Litfulo could provide a breakthrough as the first oral systemic treatment option for the condition if it gains regulatory clearance.
In the Tranquillo 2 and Tranquillo trials, the 100-mg dose resulted in 21.86% facial repigmentation and 13.02% total body improvement. The 50-mg dose showed 12.47% and 8.98% improvement in these respective metrics, compared to approximately 2% for placebo.
The players
Pfizer
Pfizer is a multinational pharmaceutical and biotechnology corporation headquartered in New York.
Incyte
Incyte is a biopharmaceutical company that produces Opzelura, currently the only FDA-approved vitiligo treatment.
AbbVie
AbbVie is a global research-based biopharmaceutical company that manufactures the drug Rinvoq.
The details
The trials measured improvements in pigmentation thresholds of 75% for the face and 50% for the body. Patients in the treatment arm reported a notable reduction in disease severity by week 52 of the study.
Timeline
July 2026: Pfizer posted topline results for the Tranquillo studies.
Late summer 2026: Rinvoq secured vitiligo approval in the European Union.
October 2, 2026: Pfizer affirmed plans to apply for regulatory review.
Week 24: Meaningful benefit was reported in clinical trials.
Week 52: Patients noted reduced disease noticeability.
The Big Picture
This development challenges the market dominance of Incyte's Opzelura by introducing an oral systemic alternative to existing topical therapies.
If approved, patients may gain access to an oral treatment that bypasses the limitations of topical applications on large body surface areas. This could offer a significant change to daily management routines for those currently limited by topical-only therapies.
The takeaway
The move toward oral systemic treatments represents a significant shift in how dermatological conditions like vitiligo are managed. Patients should discuss potential new therapeutic avenues with their doctors as clinical data continues to evolve.
Further reading
Learn more about the latest research in the Cancer section.
Live Poll
Do you prefer oral medication over topical creams for treating long-term skin conditions?
